Ziopharm Oncology (ZIOP -3.4%) slips on a downgrade to Hold at Jefferies morning. The firm also...
Ziopharm Oncology (ZIOP -3.4%) slips on a downgrade to Hold at Jefferies morning. The firm also cut its price target on the stock to $4 from $7 a share, citing increased clinical risks after the firm met with oncology experts to discuss ZIOP's palifosfamide. The discussions indicate a sub-50% probability the drug will meet its OS endpoint, which is necessary for FDA approval.
From other sites
at Nasdaq.com (Mar 25, 2015)
at CNBC.com (Jan 16, 2015)
at Benzinga.com (Jan 15, 2015)
at MarketWatch.com (Jan 14, 2015)
at Nasdaq.com (Jan 14, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs